Advanced Filter

Filter by Group

Filter by Market Availability

Displaying drugs 13401 - 13425 of 15155 in total
Inodiftagene vixteplasmid is a plasmid DNA vector encoding the diphtheria toxin A (dT-a) gene under transcriptional regulation of the promoter region of the human H19 gene (an imprinted maternally expressed non-protein coding gene).
Investigational
Investigational
PEGylated Recombinant Factor VIII is under investigation in clinical trial NCT02585960 (BAX 855 Pk-guided Dosing).
Investigational
GP2 peptide is under investigation in clinical trial NCT00524277 (Vaccine Therapy in Treating Patients With Breast Cancer).
Investigational
MW33 is a recombinant fully human antibody to SARS-CoV-2. This antibody injection is currently being investigated against COVID-19 in the clinical trial NCT04533048 (A Clinical Study to Evaluate MW33 Injection).
Investigational
Tesnatilimab is under investigation in clinical trial NCT04655807 (A Study of JNJ-64304500 as Add-on Therapy in Participants With Active Crohn's Disease).
Investigational
Coprelotamab is under investigation in clinical trial NCT04170595 (Clinical Study of Recombinant Anti-her2 Humanized Monoclonal Antibody for Injection).
Investigational
Datopotamab deruxtecan is under investigation in clinical trial NCT04656652 (Study of DS-1062A Versus Docetaxel in Previously Treated Advanced or Metastatic Non-small Cell Lung Cancer Without Actionable Genomic Alterations (TROPION-LUNG01)).
Investigational
TMV-083 is an attenuated live virus COVID-19 vaccine candidate which employs the measles vaccine as a vector . It expresses a spike protein antigen from SARS-CoV-2 .
Investigational
The V591 vaccine, part of Merck’s COVID-19 vaccine programming, was developed using a modified measles vaccine virus as a vector for COVID-19 antigen delivery . Through Merck’s acquisition of Thermis in May 2020, they were able to leverage Thermis’ platform knowledge and accelerate the development of V591 to phase I...
Investigational
Matched Description: … Merck’s acquisition of Thermis in May 2020, they were able to leverage Thermis’ platform knowledge and
Efzofitimod (ATYR1923) is a fusion protein comprised of the immuno-modulatory domain of histidyl tRNA synthetase fused to the FC region of a human antibody. It is a selective modulator of neuropilin-2 that downregulates the innate and adaptive immune response in inflammatory disease states.
Investigational
Matched Description: … It is a selective modulator of neuropilin-2 that downregulates the innate and adaptive immune response …
Zofin, previously known as Organicell Flow, is a nanoparticle-based therapeutic derived from perinatal sources which is manufactured in a way that retains the naturally occurring microRNAs without the addition of other substances .
Investigational
COVID-19 Spike-GM-CSF Protein Lactated Ringer's Injection is an intradermal injection currently being investigated in the clinical trial NCT03348670 (Discovery Stage (Proof-of-concept) COVID-19 Antigen Presentation Therapeutic Biologics (COVID-19--AP) (AP-TP-Bio)) .
Investigational
Experimental
Experimental
Tosatoxumab is a fully-human monoclonal antibody (IgG1λ) targeting the Staphylococcus aureus alpha-toxin or the S. aureus alpha-hemolysin[A191829, L31568, L31573] and thereby preserving human immune cells by protecting against destruction of host cells mediated by the toxin.
Investigational
Matched Description: … targeting the Staphylococcus aureus alpha-toxin or the S. aureus alpha-hemolysin[A191829, L31568, L31573] and
Experimental
Experimental
Displaying drugs 13401 - 13425 of 15155 in total